26893-17-4

Usage

Uses

Used in Medicinal Chemistry:
ETHYL 8-CHLORO[1,3]DIOXOLO[4,5-G]QUINOLINE-7-CARBOXYLATE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds due to its unique molecular structure and potential biological activities.
Used in Drug Discovery:
In the pharmaceutical industry, ETHYL 8-CHLORO[1,3]DIOXOLO[4,5-G]QUINOLINE-7-CARBOXYLATE is used as a starting material for the development of new drugs, particularly those targeting specific biological pathways or diseases.
Used in Research and Development:
ETHYL 8-CHLORO[1,3]DIOXOLO[4,5-G]QUINOLINE-7-CARBOXYLATE is utilized in research laboratories for studying its properties, potential interactions with biological systems, and its role in the development of novel therapeutic agents.

InChI:InChI=1/C13H10ClNO4/c1-2-17-13(16)8-5-15-9-4-11-10(18-6-19-11)3-7(9)12(8)14/h3-5H,2,6H2,1H3

Upstream product

• 17394-77-3 diethyl [[3,4-(methylenedioxy)phenylamino]methylene]malonate 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 14205-65-3 ethyl 8-hydroxy-1,3-dioxolo[4,5-g]quinoline-7-carboxylate 
• 32953-23-4 Ethyl α-ethoxycarbonyl-β-N-(5-benzodioxolyl)-N-ethylaminoacrylate 

Downstream Products

• 502172-37-4 8-(4-Butyl-phenylamino)-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid ethyl ester 
• 130373-14-7 8-(4-Butoxy-phenylamino)-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid ethyl ester 
• 130373-12-5 8-m-Tolylamino-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid ethyl ester 
• 131202-36-3 8-(2,3-Dimethyl-phenylamino)-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Design, Synthesis, and Dual Evaluation of Quinoline and Quinolinium Iodide Salt Derivatives as Potential Anticancer and Antibacterial Agents

A series of novel quinoline and quinolinium iodide derivatives were designed and synthesized to discover potential anticancer and antibacterial agents. With regard to anticancer properties, in vitro cytotoxicities against three human cancer cell lines (A-549, HeLa and SGC-7901) were evaluated. The antibacterial properties against two strains, Escherichia coli (ATCC 29213) and Staphylococcus aureus (ATCC 8739), along with minimum inhibitory concentration (MIC) values were evaluated. The target alkyliodine substituted compounds exhibited significant antitumor and antibacterial activity, of which compound 8-((4-(benzyloxy)phenyl)amino)-7-(ethoxycarbonyl)-5-propyl-[1,3]dioxolo[4,5-g]quinolin-5-ium (12) was found to be the most potent derivative with IC50 values of 4.45±0.88, 4.74±0.42, 14.54±1.96, and 32.12±3.66 against A-549, HeLa, SGC-7901, and L-02 cells, respectively, stronger than the positive controls 5-FU and MTX. Furthermore, compound 12 had the most potent bacterial inhibitory activity. The MIC of this compound against both E. coli and S. aureus was 3.125 nmol ? mL?1, which was smaller than that against the reference agents amoxicillin and ciprofloxacin.

Optimization of activity localization of quinoline derivatives: Design, synthesis, and dual evaluation of biological activity for potential antitumor and antibacterial agents

A novel of quarternary amine around a quinolinium iodide combined with even number alkyl chain were prepared in a several step in moderate yield starting from malonic ester and benzo[d][1,3]dioxol-5-amine. All of the active structure compounds were identified by nuclear magnetic resonance (NMR), such as 1H NMR, 13C NMR, infrared radiation (IR), high resolution mass spectrometry (HR-MS) and Carlo Erba Instruments CHNS-O EA1108 spectra analysis. With regard to the anticancer properties, the in vitro cytotoxicity against three human cancer cell lines (A-549, Hela and SGC-7901) were evaluated. The antibacterial properties against two human bacterial strains, Escherichia coli (ATCC 29213) and Staphylococcus aureus (ATCC 8739), along with minimum inhibitory concentration (MIC) values were evaluated. The target compounds, 5–12, exhibited significant antitumor and antibacterial activity, of which compound 12 was found to be the most potent derivative with IC50 values of 5.18 ± 0.64, 7.62 ± 1.05, 17.59 ± 0.41, and 54.45 ± 4.88 against A-549, Hela, SGC-7901, and L-02 cells, respectively, stronger than the positive control 5-FU and MTX. Furthermore, compound 12 had the most potent inhibitory activity. The MIC of this compound against Escherichia coli (ATCC 29213) and Staphylococcus aureus (ATCC 8739) was 3.125 nmol·mL?1, which was smaller than that of the reference agents, amoxicillin and ciprofloxacin.

Preparation of 1-(lower alkyl)-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acids

A process for producing a compound of the formula: SPC1 Wherein Z is CH or N; R is a lower alkyl group, a lower alkenyl group, a cycloalkyl group or a hydroxyalkyl group; R1 is a hydrogen atom or lower alkyl group; when Z is N, R2, R3 and R4 are a hydrogen atom, a halogen atom a lower alkyl group, a lower alkoxyl group, a lower hydroxyalkyl group, a lower acyloxyalkyl group, trihalogenoalkyl group, a carboxyl group, a cyano group, or an aralkyl group; when Z is CH, R2, R3 and R4 are a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxyl group, a trihalogenoalkyl group, a cyano group, a nitro group, an alkylmercapto group, a lower alkylenedioxy group, or a lower alkylene bridge attached to the quinoline nucleus, which comprises heating a compound of the formula SPC2 Wherein R, R1, R2, R3, R4 and Z are as defined above, followed, if desired, by hydrolyzing the product obtained, is disclosed. The product is useful as an antibacterial agent. An intermediate having the formula: SPC3 Wherein A is OR or a halogen atom, and R, R1, R2, R3, R4 and Z are as defined above, and a process for its preparation are also disclosed.